vs
纽约梅隆银行（BK）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
纽约梅隆银行的季度营收约是QuidelOrtho Corp的1.9倍（$1.3B vs $699.9M），纽约梅隆银行净利率更高（108.5% vs -104.7%，领先213.3%），纽约梅隆银行同比增速更快（12.7% vs -3.7%），纽约梅隆银行自由现金流更多（$4.7B vs $-94.7M），过去两年纽约梅隆银行的营收复合增速更高（13.8% vs -2.9%）
纽约梅隆银行是总部位于美国纽约的全球性金融服务机构，2007年7月由纽约银行与梅隆金融公司合并组建而成，业务覆盖全球众多市场，为机构、企业及个人客户提供专业金融服务，在资产管理、证券服务等领域拥有领先的行业地位。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
BK vs QDEL — 直观对比
营收规模更大
BK
是对方的1.9倍
$699.9M
营收增速更快
BK
高出16.5%
-3.7%
净利率更高
BK
高出213.3%
-104.7%
自由现金流更多
BK
多$4.8B
$-94.7M
两年增速更快
BK
近两年复合增速
-2.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $699.9M |
| 净利润 | $1.5B | $-733.0M |
| 毛利率 | — | — |
| 营业利润率 | — | -100.7% |
| 净利率 | 108.5% | -104.7% |
| 营收同比 | 12.7% | -3.7% |
| 净利润同比 | 26.5% | -3583.4% |
| 每股收益（稀释后） | $2.01 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BKQDEL
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.2B | $699.9M | ||
| Q2 25 | $1.2B | $613.9M | ||
| Q1 25 | $1.2B | $692.8M | ||
| Q4 24 | $1.2B | $707.8M | ||
| Q3 24 | $1.0B | $727.1M | ||
| Q2 24 | $1.0B | $637.0M | ||
| Q1 24 | $1.0B | $711.0M |
净利润BKQDEL
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | $-733.0M | ||
| Q2 25 | $1.4B | $-255.4M | ||
| Q1 25 | $1.2B | $-12.7M | ||
| Q4 24 | $1.2B | $-178.4M | ||
| Q3 24 | $1.2B | $-19.9M | ||
| Q2 24 | $1.2B | $-147.7M | ||
| Q1 24 | $1.0B | $-1.7B |
营业利润率BKQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% |
净利率BKQDEL
| Q4 25 | 108.5% | — | ||
| Q3 25 | 116.9% | -104.7% | ||
| Q2 25 | 118.3% | -41.6% | ||
| Q1 25 | 105.3% | -1.8% | ||
| Q4 24 | 96.7% | -25.2% | ||
| Q3 24 | 112.8% | -2.7% | ||
| Q2 24 | 113.4% | -23.2% | ||
| Q1 24 | 98.6% | -239.9% |
每股收益（稀释后）BKQDEL
| Q4 25 | $2.01 | — | ||
| Q3 25 | $1.88 | $-10.78 | ||
| Q2 25 | $1.93 | $-3.77 | ||
| Q1 25 | $1.58 | $-0.19 | ||
| Q4 24 | $1.53 | $-2.54 | ||
| Q3 24 | $1.50 | $-0.30 | ||
| Q2 24 | $1.52 | $-2.20 | ||
| Q1 24 | $1.25 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.1B | $98.1M |
| 总债务越低越好 | $31.9B | $2.5B |
| 股东权益账面价值 | $44.3B | $2.0B |
| 总资产 | $472.3B | $5.7B |
| 负债/权益比越低杠杆越低 | 0.72× | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资BKQDEL
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.1B | $98.1M | ||
| Q2 25 | $5.7B | $151.7M | ||
| Q1 25 | $5.4B | $127.1M | ||
| Q4 24 | $4.2B | $98.3M | ||
| Q3 24 | $6.2B | $143.7M | ||
| Q2 24 | $5.3B | $107.0M | ||
| Q1 24 | $5.3B | $78.5M |
总债务BKQDEL
| Q4 25 | $31.9B | — | ||
| Q3 25 | $32.3B | $2.5B | ||
| Q2 25 | $33.4B | $2.1B | ||
| Q1 25 | $30.9B | $2.1B | ||
| Q4 24 | $30.9B | $2.1B | ||
| Q3 24 | $33.2B | $2.2B | ||
| Q2 24 | $30.9B | $2.2B | ||
| Q1 24 | $32.4B | $2.2B |
股东权益BKQDEL
| Q4 25 | $44.3B | — | ||
| Q3 25 | $43.9B | $2.0B | ||
| Q2 25 | $44.0B | $2.8B | ||
| Q1 25 | $43.1B | $3.0B | ||
| Q4 24 | $41.3B | $3.0B | ||
| Q3 24 | $42.0B | $3.2B | ||
| Q2 24 | $40.8B | $3.2B | ||
| Q1 24 | $40.6B | $3.3B |
总资产BKQDEL
| Q4 25 | $472.3B | — | ||
| Q3 25 | $455.3B | $5.7B | ||
| Q2 25 | $485.8B | $6.4B | ||
| Q1 25 | $440.7B | $6.5B | ||
| Q4 24 | $416.1B | $6.4B | ||
| Q3 24 | $427.5B | $6.8B | ||
| Q2 24 | $428.5B | $6.7B | ||
| Q1 24 | $434.7B | $6.7B |
负债/权益比BKQDEL
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.74× | 1.23× | ||
| Q2 25 | 0.76× | 0.74× | ||
| Q1 25 | 0.72× | 0.70× | ||
| Q4 24 | 0.75× | 0.72× | ||
| Q3 24 | 0.79× | 0.68× | ||
| Q2 24 | 0.76× | 0.70× | ||
| Q1 24 | 0.80× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $4.7B | $-94.7M |
| 自由现金流率自由现金流/营收 | 352.8% | -13.5% |
| 资本支出强度资本支出/营收 | 32.4% | 7.0% |
| 现金转化率经营现金流/净利润 | 3.55× | — |
| 过去12个月自由现金流最近4个季度 | $5.2B | $-153.1M |
8季度趋势，按日历期对齐
经营现金流BKQDEL
| Q4 25 | $5.2B | — | ||
| Q3 25 | $-1.1B | $-45.5M | ||
| Q2 25 | $2.2B | $-46.8M | ||
| Q1 25 | $412.0M | $65.6M | ||
| Q4 24 | $1.6B | $63.7M | ||
| Q3 24 | $-312.0M | $117.9M | ||
| Q2 24 | $2.1B | $-97.9M | ||
| Q1 24 | $-2.7B | $-700.0K |
自由现金流BKQDEL
| Q4 25 | $4.7B | — | ||
| Q3 25 | $-1.5B | $-94.7M | ||
| Q2 25 | $1.8B | $-84.3M | ||
| Q1 25 | $92.0M | $9.4M | ||
| Q4 24 | $1.1B | $16.5M | ||
| Q3 24 | $-687.0M | $71.4M | ||
| Q2 24 | $1.7B | $-133.2M | ||
| Q1 24 | $-3.0B | $-66.8M |
自由现金流率BKQDEL
| Q4 25 | 352.8% | — | ||
| Q3 25 | -121.5% | -13.5% | ||
| Q2 25 | 152.8% | -13.7% | ||
| Q1 25 | 7.9% | 1.4% | ||
| Q4 24 | 95.2% | 2.3% | ||
| Q3 24 | -65.6% | 9.8% | ||
| Q2 24 | 169.6% | -20.9% | ||
| Q1 24 | -286.4% | -9.4% |
资本支出强度BKQDEL
| Q4 25 | 32.4% | — | ||
| Q3 25 | 35.4% | 7.0% | ||
| Q2 25 | 29.8% | 6.1% | ||
| Q1 25 | 27.6% | 8.1% | ||
| Q4 24 | 34.6% | 6.7% | ||
| Q3 24 | 35.8% | 6.4% | ||
| Q2 24 | 37.1% | 5.5% | ||
| Q1 24 | 28.7% | 9.3% |
现金转化率BKQDEL
| Q4 25 | 3.55× | — | ||
| Q3 25 | -0.74× | — | ||
| Q2 25 | 1.54× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 1.34× | — | ||
| Q3 24 | -0.26× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | -2.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BK
暂无分部数据
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
